SteroTherapeutics

SteroTherapeutics is focused on developing innovative drug therapies for orphan diseases, which are often life-threatening and affect fewer than 200,000 people in the U.S. Their lead program, ST-002, targets Cushing's syndrome, a condition caused by elevated cortisol levels, and aims to provide more effective treatments with fewer side effects. Add... itionally, they are working on ST-003, which targets Primary Sclerosing Cholangitis (PSC), a rare bile duct disorder that may also address comorbid inflammatory bowel disease (IBD). The company collaborates with leading academic institutions and organizations to advance their research and therapeutic development.Read More